2 research outputs found
Diamine Derivatives as Novel Small-Molecule, Potent, and Subtype-Selective Somatostatin SST3 Receptor Agonists
A novel
class of small-molecule, highly potent, and subtype-selective somatostatin
SST3 agonists was discovered through modification of a SST3 antagonist. As an example, (1<i>R</i>,2<i>S</i>)-<b>9</b> demonstrated not only
potent in vitro SST3 agonist activity but also in vivo SST3 agonist
activity in a mouse oral glucose tolerance test (OGTT). These agonists
may be useful reagents for studying the physiological roles of the
SST3 receptor and may potentially be useful as therapeutic agents
Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety
We report the discovery of a novel
series of DGAT1 inhibitors in
the benzimidazole class with a piperdinyl-oxy-cyclohexanecarboxylic
acid moiety. This novel series possesses significantly improved selectivity
against the A<sub>2A</sub> receptor, no ACAT1 off-target activity
at 10 μM, and higher aqueous solubility and free fraction in
plasma as compared to the previously reported pyridyl-oxy-cyclohexanecarboxylic
acid series. In particular, <b>5B</b> was shown to possess an
excellent selectivity profile by screening it against a panel of more
than 100 biological targets. Compound <b>5B</b> significantly
reduces lipid excursion in LTT in mouse and rat, demonstrates DGAT1
mediated reduction of food intake and body weight in mice, is negative
in a 3-strain Ames test, and appears to distribute preferentially
in the liver and the intestine in mice. We believe this lead series
possesses significant potential to identify optimized compounds for
clinical development